LONDON, Sept 18 (Reuters) - Germany’s Merck KGaA is launching a new late-stage Phase III clinical trial of its experimental multiple sclerosis pill cladribine, marking a step-up in investment for the product.
LONDON, Sept 18 (Reuters) - Germany’s Merck KGaA is launching a new late-stage Phase III clinical trial of its experimental multiple sclerosis pill cladribine, marking a step-up in investment for the product.